Study S002812

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of DR10624 Injection in Subjects at High Risk of Liver Fibrosis With Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction and Alcohol Associated Steatotic Liver Disease

ClinicalTrials.gov record

Registration

Registration: NCT07024212
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 110
Start: 2025-04-22
Primary completion: 2026-06-18
Lead sponsor: Zhejiang Doer Biologics Co., Ltd.
Conditions: MASLD
Interventions: DRUG:DR10624 Injection; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Changes of LFC [From baseline to Week 12]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.